NanoAssemblr™ Ignite/Ignite+ Systems: Advance, Scale And Simplify LNP Formulation

Advancing RNA and genomic medicines requires formulation workflows that remain consistent as programs move from early discovery into clinical development. A low‑volume, automated approach to lipid nanoparticle formulation helps preserve critical quality attributes while reducing setup time, operator variability, and redevelopment risk. Conserved mixer geometry and time‑invariant mixing enable predictable scale-up, allowing process parameters established at the bench to translate directly into later‑stage development and manufacturing. Shared flow rates across systems further support continuity, making it possible to evaluate upstream and downstream processes earlier while maintaining confidence in reproducibility. Together, these principles support more efficient development timelines, stronger data continuity, and better preparation for regulatory expectations without sacrificing flexibility during early research.

Access the full brochure to see how scalable LNP formulation can be built in from the start.